## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-1107-A1)

n re Application of:		)
	Beck, et al.	) Examiner: Houghtling, Richard A.
Serial I	No.: 10/532,285	) Group Art Unit: 1609
Filed:	November 22, 2005	) Confirmation No. 8774
For:	Substituted Peptides Useful in the Treatment of Alzheimer's Disease	) ) )

## RESPONSE TO THE RESTRICTION REQUIREMENT MAILED AUGUST 20, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed August 20, 2007, the Applicants select Group I, *i.e.*, claims 1-17, 30 for prosecution. Applicants further select Alzheimer's disease as the dementia-related disease.

## CONCLUSION

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2114 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

Date: September 6, 2007

Bradley W. Crawford

Registration No. 50,494